1. Home
  2. CBAN vs LUNG Comparison

CBAN vs LUNG Comparison

Compare CBAN & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Colony Bankcorp Inc.

CBAN

Colony Bankcorp Inc.

HOLD

Current Price

$17.88

Market Cap

282.0M

Sector

Finance

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$2.21

Market Cap

63.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CBAN
LUNG
Founded
1975
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Industrial Specialties
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
282.0M
63.6M
IPO Year
1998
2020

Fundamental Metrics

Financial Performance
Metric
CBAN
LUNG
Price
$17.88
$2.21
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$6.81
AVG Volume (30 Days)
101.7K
827.0K
Earning Date
01-22-2026
02-18-2026
Dividend Yield
2.57%
N/A
EPS Growth
26.78
N/A
EPS
1.59
N/A
Revenue
$122,550,000.00
$91,664,000.00
Revenue This Year
$20.97
$9.21
Revenue Next Year
$25.65
$5.03
P/E Ratio
$11.26
N/A
Revenue Growth
12.48
15.59
52 Week Low
$13.99
$1.31
52 Week High
$18.80
$9.37

Technical Indicators

Market Signals
Indicator
CBAN
LUNG
Relative Strength Index (RSI) 54.38 50.68
Support Level $17.51 $2.18
Resistance Level $18.23 $2.39
Average True Range (ATR) 0.32 0.16
MACD -0.09 -0.04
Stochastic Oscillator 29.34 11.22

Price Performance

Historical Comparison
CBAN
LUNG

About CBAN Colony Bankcorp Inc.

Colony Bankcorp Inc is a bank holding company. The bank provides a broad range of banking services to its retail and commercial customers. Its product line includes loans to small and medium-sized businesses, residential and commercial construction and land development loans, commercial real estate loans, agri-business and production loans, residential mortgage loans, consumer loans, and a variety of demand, savings, and time deposit products. The company's segments include the Banking Division, Retail Mortgage Division and small business specialty lending divisions. It generates maximum revenue from the Banking Division.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: